RBSPF
NatWest Group plc
$8.24
+1.73%
No data for this timeframe.
Vol
SEC Reports20
Recent Activity
Jun 10, 2026
SEC
This 6-K reports routine vesting of deferred share awards granted on 9 March 2026 to nine PDMRs under the 2024 Employee
6-K — Impact 2/10
Jun 5, 2026
SEC
NatWest Group plc reports weekly share buyback activity, purchasing approximately 3.1 million ordinary shares across Lon
6-K — Impact 2/10
Jun 5, 2026
SEC
NatWest Group plc filed a 6-K reporting the purchase of 563,721 ordinary shares over two days (28-29 May 2026) as part o
6-K — Impact 2/10
Analyst Ratings
7Strong Buy
11Buy
8Hold
0Sell
0Strong Sell
Latest Reports
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
20 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 0 mixed, 17 neutral. Avg impact: 2.8/10.
NEUTRAL
6-K
2/10
This 6-K reports routine vesting of deferred share awards granted on 9 March 2026 to nine PDMRs unde
Jun 10, 2026
NEUTRAL
6-K
2/10
NatWest Group plc reports weekly share buyback activity, purchasing approximately 3.1 million ordina
Jun 5, 2026
NEUTRAL
6-K
2/10
NatWest Group plc filed a 6-K reporting the purchase of 563,721 ordinary shares over two days (28-29
Jun 5, 2026
NEUTRAL
6-K
2/10
NatWest Group filed a Form 6-K on May 29, 2026, disclosing its total voting rights and capital as of
May 29, 2026
NEUTRAL
6-K
2/10
NatWest Group plc disclosed a routine PDMR share sale: Emma Crystal, CEO of Private Banking & Wealth
May 29, 2026
NEUTRAL
6-K
2/10
NatWest Group plc filed a Form 6-K reporting weekly share buyback transactions from May 18–21, 2026,
May 22, 2026
NEUTRAL
6-K
3/10
NatWest Group plc disclosed weekly share repurchases of approximately 3.67 million ordinary shares a
May 15, 2026
NEUTRAL
6-K
2/10
NatWest Group filed a Form 6-K disclosing routine PDMR share transactions: (1) grant and immediate v
May 14, 2026
BULLISH
6-K
5/10
NatWest Group plc announced that Fitch Ratings upgraded the long-term Issuer Default Ratings (IDR) a
May 13, 2026
NEUTRAL
6-K
2/10
NatWest Group plc filed a Form 6-K announcing the publication of Q1 2026 Pillar 3 documents for its
May 13, 2026
NEUTRAL
6-K
2/10
NatWest Group plc filed a Form 6-K disclosing that Robert Begbie, CEO of Commercial & Institutional,
May 12, 2026
NEUTRAL
6-K
2/10
NatWest Group plc disclosed weekly share buyback transactions on May 5, 2026, purchasing approximate
May 8, 2026
NEUTRAL
6-K
1/10
NatWest Group plc filed a 6-K reporting that PDMRs (directors) acquired shares through reinvestment
May 7, 2026
NEUTRAL
6-K
2/10
NatWest Group plc published a supplementary prospectus for its £40 billion Euro Medium Term Note Pro
May 1, 2026
BULLISH
6-K
7/10
NatWest Group reported strong Q1 2026 results with total income of £4,358m (+9.5% YoY), operating pr
May 1, 2026
BULLISH
6-K
7/10
NatWest Group reported strong Q1 2026 results with attributable profit of £1.4bn, EPS of 17.9p (+15.
May 1, 2026
NEUTRAL
6-K
1/10
NatWest Group plc filed a routine total voting rights and capital update as of April 30, 2026, discl
Apr 30, 2026
NEUTRAL
6-K
2/10
NatWest Group plc held its Annual General Meeting on 28 April 2026, and all 25 resolutions were pass
Apr 28, 2026
NEUTRAL
6-K
3/10
NatWest Group held its 2026 Annual General Meeting, with Chair Rick Haythornthwaite and CEO Paul Thw
Apr 28, 2026
NEUTRAL
6-K
4/10
NatWest Group plc announced the purchase of 6,974,844 ordinary shares over the week ending April 24,
Apr 24, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 69% buy across 26 analysts — 7 strong buy, 11 buy, 8 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $4.4B | 9.8% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $4.6B | 7.0% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $18.0B | 8.0% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $19.4B | 7.8% | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 11 | 8 | 0 | 0 | 69% | |
| May 1, 2026 | 7 | 12 | 8 | 0 | 0 | 70% | |
| Apr 1, 2026 | 7 | 13 | 7 | 0 | 0 | 74% | |
| Mar 1, 2026 | 7 | 13 | 7 | 0 | 0 | 74% | |
| Feb 1, 2026 | 7 | 12 | 6 | 2 | 0 | 70% | |
| Jan 1, 2026 | 7 | 13 | 5 | 1 | 0 | 77% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.